Capivasertib plus abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer: exploratory analysis of the proportional hazards assumption.

Transl Androl Urol · 2026 · PMC13263809 · PMID 42293846

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In the post hoc analysis of patients with 100% PTEN deficiency, the hazard ratio (HR) for overall survival (OS) was 0.77 [95% confidence interval (CI): 0.51–1.14], which did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.